1 / 30

Effects of n-3 PUFA in 6975 patients with chronic heart failure. The GISSI-HF trial

Effects of n-3 PUFA in 6975 patients with chronic heart failure. The GISSI-HF trial. Luigi Tavazzi on behalf of the GISSI-HF Investigators. GISSI-HF trial. Two nested studies to test:. N-3 polyunsaturated fatty acids hypothesis Rosuvastatin hypothesis in chronic HF patients.

geri
Download Presentation

Effects of n-3 PUFA in 6975 patients with chronic heart failure. The GISSI-HF trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effects of n-3 PUFA in 6975 patients with chronic heart failure.The GISSI-HF trial Luigi Tavazzi on behalf of the GISSI-HF Investigators

  2. GISSI-HF trial Two nested studies to test: • N-3 polyunsaturated fatty acids hypothesis • Rosuvastatin hypothesis • in chronic HF patients

  3. n-3 PUFA rationale • Experimental studiesextensively documented in cellular and animal models the favourable effects of n-3 PUFA on: • inflammatory processes (including reduction of endothelial activation and cytokine production) • platelet aggregation, • blood pressure and heart rate • ventricular function • autonomic tone • Arrhythmogenesis • Epidemiological studies showed that fish • consumption can be associated with a lower • rate of cardiac death

  4. Effect of n-3 PUFA treatment inGISSI-Prevenzione (11.323 post-MI pts) Death Non-fatal AMI Non-fatal stroke CV Death Non-fatal AMI Non-fatal stroke Overall mortality Sudden death Non-fatal events CV death 0% -5% -4% -10% n.s. -15% -15% -20% -20% -21% -25% p<0.02 p<0.008 p<0.02 -30% -30% -35% p<0.02 -40% -45% -44% -50% p<0.01 % risk reduction (GISSI-Prevenzione Investigators, Lancet 1999; 354:447)

  5. n-3 PUFA hypothesis • n-3 PUFA could improve morbidity and mortality of patients with symptomatic HF of any etiology and any level of LVEF

  6. GISSI-HF • Inclusion criteria • Patients 18 years old with chronic symptomatic heart failure (ESC Guidelines) of any etiology and with any LVEF • Exclusion criteria • Indication, contraindication or known hypersensivity to the n-3 PUFA • Severe comorbidities unlikely to be compatible with a long follow-up or requiring surgery • Acute coronary syndrome or cardiac procedure within the preceding 1 month.

  7. GISSI-HF design n. 3494 patients n-3 PUFA 1g daily n. 2285 patients Rosuvastatin 10 mg daily 4574 patients (eligible for rosuvastatin randomization) 6975 patients n. 2289 patients Placebo n. 3481 patients Placebo • n. 2401 patients not eligible for rosuvastatin: •  1576 treated with statin •  395 contraindications to statins •  430 Investigator decision 3.9-years median follow-up (6 patients have been lost to follow-up)

  8. Patients’ characteristics 6975 pts enrolled in 357 centres in Italy BMI=body mass index; SBP=systolic blood pressure

  9. Heart failure characteristics LVEF=left ventricular ejection fraction

  10. Medical history *p 0.05

  11. Concomitant medical treatment ARBs=angiotensin receptor blockers;

  12. RESULTS

  13. Primary end-points • All cause death • All-cause death or hospitalization for CV reasons

  14. Time to all-cause death n-3 PUFA: 955/3494 (27.3%) Placebo: 1014/3481 (29.1%) Absolute RR = 1.8% NNT = 56 unadjusted HR (95.5% CI) 0.93 (0.85 – 1.02), p value 0.124 adjusted HR (95.5% CI)* 0.91 (0.83 – 0.99), p value 0.041 Placebo n-3 PUFA *Cox proportional hazards model, adjusting for: hospitalisation for HF in the previous year, prior pacemaker, aortic stenosis (p<0.1).

  15. Time to all-cause death or hospitalisation for CV reasons Placebo n-3 PUFA: 1981/3494 (56.7%) Placebo: 2053/3481 (59.0%) Absolute RR = 2.3% NNT = 44 n-3 PUFA unadjusted HR (99% CI) 0.94 (0.87 – 1.02), p value 0.059 adjusted HR (99% CI)* 0·92 (0.85 – 0.99), p value 0.009 *Cox proportional hazards model, adjusting for: hospitalisation for HF in the previous year, prior pacemaker, aortic stenosis (p<0.1).

  16. Predefined Secondary Outcomes CV=cardiovascular; SCD=sudden cardiac death; HF=heart failure * Cox proportional hazards model adjusting for: hospitalisation for HF in the previous year, prior pacemaker, and aortic stenosis (p<0.1).

  17. Predefined Secondary Outcomes Vascular events MI=myocardial infarction * Cox proportional hazards model adjusting for: hospitalisation for HF in the previous year, prior pacemaker, and aortic stenosis (p<0.1).

  18. Effects of n-3 PUFA on arrhythmic events

  19. Predefined Subgroup analysis 0.92 Age <69 years (median) 0.96 Age ≥69 years (median) 0.94 LVEF ≤40% 1.02 LVEF >40% 0.95 Ischemic etiology 0.94 Not ischemic etiology 0.93 NYHA II 0.96 NYHA III-IV 0.89 Diabetes 0.96 No diabetes 0.91 Total cholesterol# ≤188 mg/dL 0.96 Total cholesterol# >188 mg/dL Placebo better N-3 PUFA better

  20. Permanent treatment discontinuations

  21. Per protocol analysis (4,994 patients) Time to Combined Endpoint = time to death or CV hospitalization, whichever comes first Time to all-cause death unadjusted HR (95.5% CI) 0.88 (0.79–0.98), p 0.019 adjusted HR (95.5% CI)* 0.86 (0.77–0.95), p0.004 0.7 Placebo 1396/2482 (56.2%) 0.6 0.5 Placebo 725/2482 (29.2%) n-3 PUFA 1339/2512 (53.3%) 0.4 0.3 unadjusted HR (99% CI) 0.93 (0.84–1.03) p 0.064 adjusted HR (99% CI)* 0.92 (0.84–1.02) p 0.036 0.2 n-3 PUFA 658/2512 (26.2%) 0.1 0.0 0 182 364 546 728 910 1092 1274 1456 1638 0 182 364 546 728 910 1092 1274 1456 1638 *Cox proportional hazards model, adjusted for: hospitalization for HF in the previous year, aortic stenosis, prior revascularization and history of paroxistical AF (p<0.1)

  22. Adverse drug reactions ADR=adverse drug reaction

  23. GISSI-HF Conclusions • Long-term administration of 1g/day n-3 PUFA was effective in reducing both all-cause mortality and hospitalisations for CV reasons in the large population of patients with HF included in the pragmatic GISSI-HF trial , in a context of usual care.

  24. GISSI-HF Conclusions • The benefit was moderate, smaller than expected • (RRR 7%-9% vs assumed 15%) but it was: • - obtained on top of recommended therapies • - consistent across all predefined subgroups • - supported by per-protocol analysis (RRR 12%-14%) • No adverse events were noted • In chronic heart failure patients the n-3 PUFA treatment is moderately effective, safe, simple (once daily) and cheap.

  25. Acknowledgements The GISSI-HF trial was planned, conducted and analyzed by the GISSI group which has full ownership of the data. SPA, Pfizer, Sigma Tau and AstraZeneca concurred to fund the study.

  26. Acknowledgements • GISSI is endorsed by • Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Firenze, Italy; • Ist.Ricerche Farmacologiche Mario Negri, Milan, Italy; • Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.

  27. Committees Steering Committee L Tavazzi (Chairman), G Tognoni (Co-Chairman), MG Franzosi, R Latini, AP Maggioni, R Marchioli, GL Nicolosi, M Porcu Data and Safety Monitoring Board S Yusuf (Chairman), F Camerini, JN. Cohn, A Decarli, B Pitt, PA. Poole-Wilson, Peter Sleight, Clinical Endpoint Committee E Geraci (Chairman), M Scherillo (Co-Chairman), G Fabbri (Coordinator), B Bartolomei (Secretary), D Bertoli, F Cobelli, CFresco, A Ledda, G Levantesi, C Opasich, F Rusconi, G Sinagra, F Turazza, A Volpi

  28. Coordinating Centers Clinical Monitoring M Ceseri (coordinator), G Alongi, A Atzori, F Bambi, D Bastarolo, F Bianchini, I Cangioli, V Canu, C Caporusso, G Cenni, L Cintelli, M Cocchio, A Confente, E Fenicia, G Friso, M Gianfriddo, G Grilli, B Lazzaro, G Lonardo, A Luise, R Nota, M Orlando, R Petrolo, C Pierattini, V Pierota, A Provenzani, V Quartuccio, A Ragno, CSerio, A Spolaor, A Tafi, E Tellaroli Database Management and Statistics D Lucci, S Barlera, M Gorini, L Gonzini, V Milani, G Orsini Regulatory, Administrative and Secretariat E Bianchini, S Cabiddu, I Cangioli, L Cipressa, ML Cipressa, G Di Bitetto, B Ferri, L Galbiati, A Lorimer, C Pera, P Priami, A Vasamì

  29. GISSI-HF Subprojects Ventricular Remodeling: Echo:S Ghio, E Ghizzardi Biohumoral:R Latini, S Masson Genetic: M GFranzosi, L Crociati Arrhythmic/Autonomic :MT La Rovere Exercise Capacity:U Corrà Quality of Life and Depression: P Di Giulio Implantable Cardiac Defibrillator:A Finzi

More Related